Literature DB >> 31446029

Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema.

Masahiko Sugimoto1, Atushi Ichio2, Daiki Mochida3, Yumiho Tenma2, Ryohei Miyata2, Hisashi Matsubara2, Mineo Kondo2.   

Abstract

PURPOSE: To evaluate the effects of intravitreal aflibercept (IVA) on the number of microaneurysms and sizes of nonperfused areas (NPAs) in eyes with diabetic macular edema (DME).
DESIGN: Interventional, prospective study. PARTICIPANTS: Twenty-five eyes of 25 DME patients (average age, 64.0±8.8 years) were treated with 3 consecutive monthly IVA injections.
METHODS: Fluorescein angiography (FA) and OCT were performed before the IVA injections (baseline) and at 1 week after the IVA treatment. The number of microaneurysms and the ischemic index (ISI), a measure of NPA, were determined. The correlations between central retinal thickness (CRT) and number of microaneurysms and the ISI were also determined. MAIN OUTCOME MEASURES: The mean number of microaneurysms and NPA evaluated as the ISI.
RESULTS: At baseline, the mean CRT was 485.7±90.6 μm. After treatment, the mean CRT was reduced significantly to 376.9±81.6 μm (P = 0.1 × 10-5, repeated analysis of variance). The mean number of microaneurysms was decreased significantly from 49.6±33.2 at baseline to 24.8±18.1 at 3 months after the initial treatment. This was a 50.4±21.2% reduction (P = 0.3 × 10-5, paired t test). The mean ISI was also decreased significantly from 55.5±20.4% at baseline to 28.8±16.8% after treatment (P = 0.3 × 10-5, paired t test). This was a reduction of 43.3±28.5%. A significant correlation was found between the CRT and number of microaneurysms at both baseline (r = 0.56; P = 0.004) and after treatment (r = 0.53; P = 0.006). A significant correlation was found between CRT and ISI at baseline (r = -0.39; P = 0.03) but not after treatment (r = -0.06; P = 0.79).
CONCLUSIONS: The reduction in the number of microaneurysms was correlated with reduction in CRT.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31446029     DOI: 10.1016/j.oret.2019.06.005

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  5 in total

Review 1.  Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.

Authors:  Irini Chatziralli; Sara Touhami; Maria Vittoria Cicinelli; Chrysa Agapitou; Eleni Dimitriou; George Theodossiadis; Panagiotis Theodossiadis
Journal:  Eye (Lond)       Date:  2021-08-18       Impact factor: 3.775

Review 2.  The Evolving Treatment of Diabetic Retinopathy.

Authors:  Sam E Mansour; David J Browning; Keye Wong; Harry W Flynn; Abdhish R Bhavsar
Journal:  Clin Ophthalmol       Date:  2020-03-04

3.  Early Visual Functional Outcomes and Morphological Responses to Anti-Vascular Growth Factor Therapy in Diabetic Macular Oedema Using Optical Coherence Tomography Angiography.

Authors:  Supriya Dabir; Mohan Rajan; Liji Parasseril; Vaidehi Bhatt; Preetam Samant; C A B Webers; T T J M Berendschot
Journal:  Clin Ophthalmol       Date:  2021-01-28

4.  Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan.

Authors:  Ming-Chieh Hsieh; Chieh-Yin Cheng; Kun-Hsien Li; Chih-Chun Chuang; Jian-Sheng Wu; Sheng-Ta Lee; Wei-Yang Lu; Shin-Lin Chiu; Yu-Ling Liu; San-Ni Chen
Journal:  Sci Rep       Date:  2022-01-13       Impact factor: 4.379

5.  Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy.

Authors:  Atsushi Ichio; Masahiko Sugimoto; Hisashi Matsubara; Daiki Mochida; Kumiko Kato; Mineo Kondo
Journal:  Transl Vis Sci Technol       Date:  2020-10-06       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.